[1]
|
Döhner, H., Wei, A.H., Appelbaum, F.R., et al. (2022) Diagnosis and Management of AML in Adults: 2022 Recom-mendations from an International Expert Panel on Behalf of the ELN. Blood, 140, 1345-1377.
https://doi.org/10.1182/blood.2022016867
|
[2]
|
Czabotar, P.E. and Garcia-Saez, A.J. (2023) Mechanisms of BCL-2 Family Proteins in Mitochondrial Apoptosis. Nature Reviews Molecular Cell Biology, 24, 732-748. https://doi.org/10.1038/s41580-023-00629-4
|
[3]
|
Diepstraten, S.T., Anderson, M.A., Czabotar, P.E., et al. (2022) The Manipulation of Apoptosis for Cancer Therapy Using BH3-Mimetic Drugs. Nature Reviews Cancer, 22, 45-64. https://doi.org/10.1038/s41568-021-00407-4
|
[4]
|
中国临床肿瘤学会白血病专家委员会. 维奈克拉治疗恶性血液病临床应用指导原则(2021年版) [J]. 白血病∙淋巴瘤, 2021, 30(12): 710-718.
|
[5]
|
中华医学会血液学分会白血病淋巴瘤学组. 成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2023年版) [J]. 中华血液学杂志, 2023, 44(9): 705-712.
|
[6]
|
Konopleva, M., Pollyea, D.A., Potluri, J., et al. (2016) Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Dis-covery, 6, 1106-1117.
https://doi.org/10.1158/2159-8290.CD-16-0313
|
[7]
|
DiNardo, C.D., Jonas, B.A., Pullarkat, V., et al. (2020) Aza-citidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. New England Journal of Medicine, 383, 617-629. https://doi.org/10.1056/NEJMoa2012971
|
[8]
|
Kwag, D., Cho, B.S., Bang, S.Y., et al. (2022) Venetoclax with Decitabine versus Decitabine Monotherapy in Elderly Acute Myeloid Leukemia: A Propensity Score-Matched Analysis. Blood Cancer Journal, 12, Article No. 169.
https://doi.org/10.1038/s41408-022-00770-x
|
[9]
|
Wei, A.H., Montesinos, P., Ivanov, V., et al. (2020) Venetoclax plus LDAC for Newly Diagnosed AML Ineligible for Intensive Chemotherapy: A Phase 3 Randomized Place-bo-Controlled Trial. Blood, 135, 2137-2145.
https://doi.org/10.1182/blood.2020004856
|
[10]
|
Kadia, T.M., Reville, P.K., Wang, X., et al. (2022) Phase II Study of Venetoclax Added to Cladribine plus Low-Dose Cytarabine Alternating with 5-Azacitidine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology, 40, 3848-3857. https://doi.org/10.1200/JCO.21.02823
|
[11]
|
Stahl, M., Menghrajani, K., Derkach, A., et al. (2021) Clinical and Molecular Predictors of Response and Survival Following Venetoclax Therapy in Relapsed/Refractory AML. Blood Ad-vances, 5, 1552-1564.
https://doi.org/10.1182/bloodadvances.2020003734
|
[12]
|
Weng, G., Zhang, Y., Yu, G., et al. (2023) Genetic Char-acteristics Predict Response to Venetoclax plus Hypomethylating Agents in Relapsed or Refractory Acute Myeloid Leu-kemia. Journal of Internal Medicine, 293, 329-339.
https://doi.org/10.1111/joim.13581
|
[13]
|
Todisco, E., Papayannidis, C., Fracchiolla, N., et al. (2023) AVALON: The Italian Cohort Study on Real‐Life Efficacy of Hypomethylating Agents plus Venetoclax in Newly Diagnosed or Re-lapsed/Refractory Patients with Acute Myeloid Leukemia. Cancer, 129, 992-1004. https://doi.org/10.1002/cncr.34608
|
[14]
|
Jin, H., Zhang, Y., Yu, S., et al. (2023) Venetoclax Combined with Aza-citidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial. Journal of Hematology & Oncology, 16, Article No. 42.
https://doi.org/10.1186/s13045-023-01437-1
|
[15]
|
Wang, H., Mao, L., Yang, M., et al. (2022) Venetoclax plus 3 + 7 Daunorubicin and Cytarabine Chemotherapy as First-Line Treatment for Adults with Acute Myeloid Leukaemia: A Multicentre, Single-Arm, Phase 2 Trial. The Lancet. Haematology, 9, E415-E424. https://doi.org/10.1016/S2352-3026(22)00106-5
|
[16]
|
Di Nardo, C.D., Lachowiez, C.A., Takahashi, K., et al. (2022) Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. American Journal of Hematology, 97, 1035-1043.
https://doi.org/10.1002/ajh.26601
|
[17]
|
Di Nardo, C.D., Lachowiez, C.A., Takahashi, K., et al. (2021) Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Mye-loid Leukemia. Journal of Clinical Oncology, 39, 2768-2778. https://doi.org/10.1200/JCO.20.03736
|
[18]
|
Kadia, T.M., Reville, P.K., Borthakur, G., et al. (2021) Venetoclax plus Intensive Chemotherapy with Cladribine, Idarubicin, and Cytarabine in Patients with Newly Diagnosed Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome: A Cohort from a Single-Centre, Single-Arm, Phase 2 Trial. The Lancet. Haematology, 8, E552-E561.
https://doi.org/10.1016/S2352-3026(21)00192-7
|
[19]
|
Suo, X., Zheng, F., Wang, D., et al. (2023) Venetoclax Combined with Daunorubicin and Cytarabine (2 + 6) as Induction Treatment in Adults with Newly Diagnosed Acute Myeloid Leukemia: A Phase 2, Multicenter, Single-Arm Trial. Experimental Hematology & Oncology, 12, Article No. 45. https://doi.org/10.1186/s40164-023-00409-y
|
[20]
|
Wang, H., Yao, Y., Mao, L., et al. (2023) Venetoclax plus “2 + 5” Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated De Novo Acute Myeloid Leukaemia: A Single-Centre Retrospective Analysis. British Journal of Haematology, 201, 568-572. https://doi.org/10.1111/bjh.18709
|
[21]
|
Janssen, M., et al. (2022) Venetoclax Synergizes with Gilteritinib in FLT3 Wild-Type High-Risk Acute Myeloid Leukemia By Suppressing MCL-1. Blood, 140, 2594-2610. https://doi.org/10.1182/blood.2021014241
|
[22]
|
Daver, N., Perl, A.E., Maly, J., et al. (2022) Venetoclax plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 40, 4048-4059. https://doi.org/10.1200/JCO.22.00602
|
[23]
|
Issa, G.C. and Di Nardo, C.D. (2021) Acute Myeloid Leukemia with IDH1 and IDH2 Mutations: 2021 Treatment Algorithm. Blood Cancer Journal, 11, Article No. 107. https://doi.org/10.1038/s41408-021-00497-1
|
[24]
|
Pollyea, D.A., Di Nardo, C.D., Arellano, M.L., et al. (2022) Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. Clinical Cancer Research, 28, 2753-2761.
https://doi.org/10.1158/1078-0432.CCR-21-3467
|
[25]
|
Cathelin, S., Sharon, D., Subedi, A., et al. (2022) Enasidenib-Induced Differentiation Promotes Sensitivity to Venetoclax in IDH2-Mutated Acute Myeloid Leukemia. Leukemia, 36, 869-872. https://doi.org/10.1038/s41375-021-01468-y
|
[26]
|
Jasra, S., Kazemi, M., Shah, N., et al. (2021) Case Report of Combination Therapy with Azacytidine, Enasidenib and Venetoclax in Primary Refractory AML. Experimental Hematology & Oncology, 10, Article No. 1.
https://doi.org/10.1186/s40164-020-00186-y
|
[27]
|
Molica, M., Perrone, S., Mazzone, C., et al. (2021) CD33 Ex-pression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin. Cancers, 13, Article No. 3214. https://doi.org/10.3390/cancers13133214
|
[28]
|
Morse, J.W., Rios, M., Ye, J., et al. (2023) Antibody Therapies for the Treatment of Acute Myeloid Leukemia: Exploring Current and Emerging Therapeutic Targets. Expert Opinion on Investigational Drugs, 32, 107-125.
https://doi.org/10.1080/13543784.2023.2179482
|
[29]
|
Daver, N.G., Vyas, P., Kambhampati, S., et al. (2023) Tol-erability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined with Azacitidine in Pa-tients with Previously Untreated AML: Phase Ib Results. Journal of Clinical Oncology, 41, 4893-4904. https://doi.org/10.1200/JCO.22.02604
|
[30]
|
Lane, A.A., Garcia, J.S., Raulston, E.G., et al. (2023) Phase 1b Trial of Tagraxofusp in Combination with Azacitidine with or without Venetoclax in Acute Myeloid Leukemia. Blood Advances, 8, 591-602.
https://doi.org/10.1182/bloodadvances.2023011721
|
[31]
|
DiNardo, C.D., Rausch, C.R., Benton, C., et al. (2018) Clinical Experience with the BCL2-Inhibitor Venetoclax in Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies. American Journal of Hematology, 93, 401-407. https://doi.org/10.1002/ajh.25000
|
[32]
|
Dhakal, P., Bates, M., Tomasson, M.H., et al. (2023) Acute Myeloid Leu-kemia Resistant to Venetoclax-Based Therapy: What Does the Future Hold? Blood Reviews, 59, Article ID: 101036. https://doi.org/10.1016/j.blre.2022.101036
|
[33]
|
Carter, B.Z., Mak, P.Y., Tao, W., et al. (2022) Targeting MCL-1 Dysregulates Cell Metabolism and Leukemia-Stroma Interactions and Resensitizes Acute Myeloid Leukemia to BCL-2 Inhibition. Haematologica, 107, 58-76.
https://doi.org/10.3324/haematol.2020.260331
|
[34]
|
Moujalled, D.M., Brown, F.C., Chua, C.C., et al. (2023) Ac-quired Mutations in BAX Confer Resistance to BH3-Mi- metic Therapy in Acute Myeloid Leukemia. Blood, 141, 634-644. https://doi.org/10.1182/blood.2022016090
|
[35]
|
DiNardo, C.D., Tiong, I.S., Quaglieri, A., et al. (2020) Molecular Patterns of Response and Treatment Failure after Frontline Venetoclax Combinations in Older Patients with AML. Blood, 135, 791-803.
https://doi.org/10.1182/blood.2019003988
|
[36]
|
Zhang, Q., Riley-Gillis, B., Han, L., et al. (2022) Activation of RAS/MAPK Pathway Confers MCL-1 Mediated Acquired Resistance to BCL-2 Inhibitor Venetoclax in Acute Myeloid Leukemia. Signal Transduction and Targeted Therapy, 7, Article No. 51. https://doi.org/10.1038/s41392-022-00958-4
|
[37]
|
Nechiporuk, T., Kurtz, S.E., Nikolova, O., et al. (2019) The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells. Cancer Discovery, 9, 910-925.
https://doi.org/10.1158/2159-8290.CD-19-0125
|
[38]
|
Chen, X., Glytsou, C., Zhou, H., et al. (2019) Targeting Mi-tochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment. Cancer Discovery, 9, 890-909. https://doi.org/10.1158/2159-8290.CD-19-0117
|
[39]
|
Pollyea, D.A., Stevens, B.M., Jones, C.L., et al. (2018) Ve-netoclax with Azacitidine Disrupts Energy Metabolism and Targets Leukemia Stem Cells in Acute Myeloid Leukemia Pa-tients. Nature Medicine, 24, 1859-1866.
https://doi.org/10.1038/s41591-018-0233-1
|
[40]
|
Stevens, B.M., Jones, C.L., Pollyea, D.A., et al. (2020) Fatty Ac-id Metabolism Underlies Venetoclax Resistance in Acute Myeloid Leukemia Stem Cells. Nature Cancer, 1, 1176-1187. https://doi.org/10.1038/s43018-020-00126-z
|
[41]
|
Jones, C.L., Stevens, B.M., Pollyea, D.A., et al. (2020) Nico-tinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. Cell Stem Cell, 27, 748-764.E4.
https://doi.org/10.1016/j.stem.2020.07.021
|
[42]
|
Kuusanmäki, H., Leppä, A.M., Pölönen, P., et al. (2020) Pheno-type-Based Drug Screening Reveals Association between Venetoclax Response and Differentiation Stage in Acute Mye-loid Leukemia. Haematologica, 105, 708-720.
https://doi.org/10.3324/haematol.2018.214882
|
[43]
|
Pei, S., Pollyea, D.A., Gustafson, A., et al. (2020) Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Cancer Discovery, 10, 536-551.
https://doi.org/10.1158/2159-8290.CD-19-0710
|
[44]
|
White, B.S., Khan, S.A., Mason, M.J., et al. (2021) Bayesian Multi-Source Regression and Monocyte-Associated Gene Expression Predict BCL-2 Inhibitor Resistance in Acute Mye-loid Leukemia. NPJ Precision Oncology, 5, Article No. 71. https://doi.org/10.1038/s41698-021-00209-9
|